Outcome Capital Continues to Expand with the Addition of Charles Simmons
2024年8月7日 - 9:30PM
ビジネスワイヤ(英語)
Appointment of Charles Simmons as Managing
Director continues to strengthen Outcome’s capabilities
Outcome Capital, LLC, a highly specialized life sciences and
healthcare advisory and investment banking firm, today announced
that Charles Simmons, J.D. has been appointed to the role of
Managing Director in its Boston office. The firm continues to
expand its Life Sciences and Healthcare practices deploying its
unique market-aligned, strategy-driven platform, providing mergers
and acquisitions, partnerships, and strategic advisory
services.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240807978894/en/
Charles Simmons, Managing Director,
Outcome Capital (Photo: Business Wire)
“At this time of dynamic change in healthcare due to
technology-driven advances in life sciences, I am excited to join a
team of exceptional professionals with deep strategic knowledge on
Outcome Capital’s premium and growing platform,” commented
Charles.
Charles Simmons brings over 25 years’ experience as a business
leader driving transformational change in companies across the Life
Sciences sector. His background includes extensive global work in a
range of corporate settings (public, development stage, private
equity/PE) and sectors (pharma, pharma services, med-tech). He has
a proven track record partnering with investors, boards, CEOs, and
other key stakeholders addressing significant business issues,
articulating and building agreement around transformational change,
and providing hands-on leadership to deliver results including
leading multi-billion-dollar transactions.
Dr. Oded Ben-Joseph, Managing Partner at Outcome Capital
commented, “We continue to expand our specialized strategy-led
execution model, which allow us to provide premium services to our
clients, successfully navigating their businesses through
significant inflection points, and toward successful transactions.
Charles’ sector expertise and M&A experience will be
instrumental in Outcome’s growth and is exemplary of the firm’s
underlying philosophy of combining scientific and clinical
expertise with financial and transactional acumen.”
Prior to joining Outcome, Charles was Chief Growth Officer at
Corium, Inc., a commercial-stage biopharmaceutical company. He was
an instrumental leader in the divestiture of G&W Laboratories’
historic businesses and subsequent investment into Flipt LLC, a
mission-driven healthcare technology and services company.
Previously as President, Commercial Development & Operations
with Idis Pharmaceuticals, a pharma services business, Charles
drove improvements in operational metrics and led the group that
re-entered the clinical sourcing business. Prior to that, Charles
served as VP, Corporate Development at Bristol-Myers Squibb Company
(BMS) for almost a decade where he was instrumental in several
transactions that transformed BMS. Charles launched his career as
an Associate for the major New York law firm, Shearman &
Sterling.
Charles holds a J.D. from Pace University School of Law and a
B.A. degree from Tufts University.
About Outcome Capital
Outcome Capital is a highly specialized life sciences and
healthcare advisory and investment banking firm, providing
innovative companies with a value-added, market-aligned approach to
mergers & acquisitions, partnering and corporate finance. The
firm leverages its proven ‘strategy-led execution’ approach to
value enhancement by assisting management teams and their boards in
navigating both financial and corporate markets and implementing
the best path for success. The firm’s strength stems from its
multi-disciplinary, industry experts who draw from their broad
relationships and a wide range of scientific, operational,
strategic and transactional expertise across the value chain.
Comprised of former CEOs, business development executives, venture
capitalists, PhD/MD-level scientists and clinicians, and
experienced commercialization experts, Outcome’s team is driven to
propel innovation from bench to bedside.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240807978894/en/
Outcome Capital - Media Michelle Linn Linnden
Communications michelle@linndencom.com Outcome Capital Steve
Holstein SHolstein@outcomecapital.com